Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL

Inclusion Criteria

• Clinical or pathological diagnosis of CLL/SLL according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) diagnosis guideline or pathological diagnosis of FL, for whom the Investigator has decided that PI3K-inhibitor treatment is the appropriate therapy
• Patients previously treated with PI3K-inhibitors are eligible for this study if they:
• Are restarting treatment with PI3K-inhibitor at enrollment, or
• Restarted PI3K-inhibitor treatment within 3 treatment cycles prior to enrollment
• Patients newly treated with PI3K-inhibitors are eligible for this study if they:
• Are starting treatment with PI3K-inhibitors at enrollment, or
• Started on PI3K-inhibitor treatment within 3 treatment cycles prior to enrollment
• ≥18 years of age at time consent is provided to participate in this study
• For patients treated with PI3K-inhibitors prior to enrollment in the study, availability of documentation of previous PI3K-inhibitor treatment, including the start date of previous or current PI3K-inhibitor treatment in patient charts or medical records
• Patient is willing and able to provide a signed and dated Institutional Review Board (IRB)-approved informed consent form (ICF)

Exclusion Criteria

• Not applicable